ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Potential of hTERT mRNA for the management of advanced head and neck squamous cell carcinoma.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposehTERT messenger RNA (hTERT mRNA) has been detected in peripheral blood of different cancer patients and its elevation seems related to clinicopathological parameters and treatment efficacy. The objectives are analyzing if hTERT mRNA levels are increased in cancer patients, detecting it they change after treatment and determining if they could be useful in disease monitoring.
methodsA prospective, analytical, case-control study was conducted, in which peripheral blood of 37 head and neck squamous cell cancer patients and 30 healthy donors were obtained. hTERT mRNA expression levels were determined by PCR-RT. Follow-up of cancer patients was carried out during one year with blood extractions at 7 days for surgical patients, and 1, 2, 6 and 12 months after finishing treatment for all patients.
resultshTERT mRNA expression levels were elevated in plasma of cancer patients (0,75) compared to controls (0,5) (p = 0.003). Patients in more advanced stages had higher hTERT mRNA levels (p = 0.008). hTERT mRNA levels during follow-up did not change significantly at the different time points but showed a tendency to decrease, comparing treatment responders with tumour persistence patients. An early decrease of hTERT mRNA levels was observed in the five cured patients who underwent surgery.
conclusionsDetection of plasma hTERT mRNA after surgery might help to identify patients with better prognosis. Quantitation of plasma hTERT mRNA could be a complementary tool for diagnosis, but still further studies are needed to clarify the role and causes of variable circulating hTERT mRNA levels for prognosis and follow-up.
Indexed as
Identifiers
42507204What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.